User profiles for Christy M. Hebner
 | Christy HebnerVir Biotechnology Verified email at vir.bio Cited by 5191 |
[HTML][HTML] Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab
…, N Scott, AL Cathcart, CM Hebner… - … England Journal of …, 2021 - Mass Medical Soc
Background Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization
or death in older patients and those with underlying conditions. Sotrovimab is a pan-…
or death in older patients and those with underlying conditions. Sotrovimab is a pan-…
Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity
CM Hebner, LA Laimins - Reviews in medical virology, 2006 - Wiley Online Library
Human papillomaviruses (HPVs) are small double‐stranded DNA viruses that infect the
cutaneous and mucosal epithelium. Infection by specific HPV types has been linked to the …
cutaneous and mucosal epithelium. Infection by specific HPV types has been linked to the …
[HTML][HTML] SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape 1 , 2 – 3 , have
activity against diverse sarbecoviruses 4 , 5 , 6 – 7 , and be highly protective through viral …
activity against diverse sarbecoviruses 4 , 5 , 6 – 7 , and be highly protective through viral …
The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2
VIR-7831 and VIR-7832 are dual action monoclonal antibodies (mAbs) targeting the spike
glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-7831 …
glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-7831 …
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial
…, M Mader, E Albanis, D Jiang, CM Hebner… - Journal of …, 2013 - Elsevier
Background & Aims Sofosbuvir (formerly GS-7977) is a pyrimidine nucleotide analog inhibitor
of the hepatitis C virus (HCV) NS5B polymerase. We assessed the safety, tolerability, …
of the hepatitis C virus (HCV) NS5B polymerase. We assessed the safety, tolerability, …
Sonic hedgehog activates mesenchymal Gli1 expression during prostate ductal bud formation
…, WS Catbagan, RJ Laciak, DH Barnett, CM Hebner… - Developmental …, 2002 - Elsevier
Ductal budding in the developing prostate is a testosterone-dependent event that involves
signaling between the urogenital sinus epithelium (UGE) and urogenital sinus mesenchyme (…
signaling between the urogenital sinus epithelium (UGE) and urogenital sinus mesenchyme (…
Mesenchymal factor bone morphogenetic protein 4 restricts ductal budding and branching morphogenesis in the developing prostate
…, DH Barnett, J Lee, JQ Clemens, CM Hebner… - Developmental …, 2001 - Elsevier
The budding of the urogenital sinus epithelium into the surrounding mesenchyme signals
the onset of prostate morphogenesis. The epithelial and mesenchymal factors that regulate …
the onset of prostate morphogenesis. The epithelial and mesenchymal factors that regulate …
[HTML][HTML] The HCV non-nucleoside inhibitor tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function
CM Hebner, B Han, KM Brendza, M Nash, M Sulfab… - PLoS …, 2012 - journals.plos.org
Tegobuvir (TGV) is a novel non-nucleoside inhibitor (NNI) of HCV RNA replication with
demonstrated antiviral activity in patients with genotype 1 chronic HCV infection. The mechanism …
demonstrated antiviral activity in patients with genotype 1 chronic HCV infection. The mechanism …
Human papillomaviruses target the double-stranded RNA protein kinase pathway
The double-stranded RNA protein kinase (PKR) pathway plays a vital role in the innate
immune response to viral infection. Activation of PKR following virus entry can lead to a …
immune response to viral infection. Activation of PKR following virus entry can lead to a …
[HTML][HTML] Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials
Background & Aims Current therapy for chronic hepatitis B virus (cHBV) infection involves
lifelong treatment. New treatments that enable HBV functional cure would represent a clinically …
lifelong treatment. New treatments that enable HBV functional cure would represent a clinically …
